{"Clinical Trial ID": "NCT00004092", "Intervention": ["INTERVENTION 1:", "Weapons I (ACT)", "Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC is reinjected on days -2 and 0. G-CSF at 5 ug/kg IV is administered from day 0 and continues until blood count recovers.", "Filgrastim: given IV or subcutaneously", "Cyclophosphamide: given IV", "Doxorubicin hydrochloride: IV", "Paclitaxel: given IV", "Transplantation of peripheral blood stem cells: patients receive autologous peripheral blood stem cells", "INTERVENTION 2:", "Weapons II (STAMP V)", "Patients receive cyclophosphamide 1.5 g/m2/day IV, carboplatin 200 mg/m2/day IV and thiotepa 125 mg/m2/day IV for 24 hours on days -7 to -4. PBSC is reinjected on day -2 and 0 and G-CSF at 5ug/kg IV is administered as in arm I.", "Filgrastim: given IV or subcutaneously", "Carboplatin: under IV", "Cyclophosphamide: given IV", "\u00b7 thiotepa: under IV", "Transplantation of peripheral blood stem cells: patients receive autologous peripheral blood stem cells"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "\u00b7 High-risk primary breast cancer has been proven histologically with less than 60% chance of survival without 3-year progression from diagnosis", "Step II with at least 10 positive axillary nodes OR", "Step IIIA or IIIB", "No histologically proven metastasis of the bone marrow", "No CNS metastases", "- Hormonal receptor status:", "Known situation of hormone receptors", "CHARACTERISTICS OF PATIENTS:", "Age:", "- 60 years or less", "Status of menopause:", "Unspecified", "Status:", "Karnofsky 80-100%", "Life expectancy:", "See Disease Characteristics", "Haematopoietic:", "Number of neutrophils at least 1,500/mm3", "Number of platelets of at least 100 000/mm^3", "Hepatic:", "Bilirubine not exceeding 1.5 mg/dL", "- SGOT or SGPT not exceeding 2 times the upper limit of normal", "Negative to hepatitis B antigen", "- Renal:", "- Creatinine not exceeding 1,2 mg/dL", "At least 70 mL/min creatinine clearance", "No previous hemorrhagic cystitis", "Cardiovascular disorders:", "At least 55% ejection fraction by MUGA", "No significant anterior valvular heart disease or arrhythmia", "Pulmonary:", "FEV_1 at least 60 % of the forecast", "- PO_2 at least 85 mm Hg on ambient air", "- PCO_2 at least 43 mm Hg on ambient air", "DLCO at least 60% lower limit of forecast", "Other:", "No other prior malignancy except skin cancer of squamous or basal cell cells or stage I or in situ cervix carcinoma", "No CNS malfunction that would prevent compliance", "Negative to HIV", "No sensitivity to E. coli derivatives", "Not pregnant", "Fertile patients should use effective contraception", "THERAPE PRIOR CONCURENT:", "Biological therapy:", "Unspecified", "- Chemotherapy:", "At least 4 weeks since previous chemotherapy", "No previous total dose of doxorubicin greater than 240 mg/m2", "No previous paclitaxel total dose of at least 750 mg/m2", "No more than 12 months since previous conventional adjuvant-dose chemotherapy", "Endocrinotherapy:", "At least 4 weeks since prior hormonal treatment", "Radiotherapy:", "At least 4 weeks since previous radiation therapy", "No anterior radiation on left chest wall", "Surgery:", "Unspecified"], "Results": ["Performance measures:", "Five-year relapse-free survival", "Patients who did not experience recidivism or death were censored at the time of the last follow-up. Survival rates were estimated using the Kaplan-Meier method.", "Calendar: Five years", "Results 1:", "Title of arm/group: Arm I (ACT)", "Description of arms/group: Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC is reinjected on days -2 and 0. G-CSF at 5 ug/kg IV is administered from day 0 and continues until the blood count recovers.", "Filgrastim: given IV or subcutaneously", "Cyclophosphamide: given IV", "Doxorubicin hydrochloride: IV", "Paclitaxel: given IV", "Transplantation of peripheral blood stem cells: patients receive autologous peripheral blood stem cells", "Total number of participants analysed: 21", "Type of measurement: Number", "Unit of measure: percentage of participants 47 (24 to 67)", "Results 2:", "Title of arm/group: Arm II (STAMP V)", "Description of the arm/group: Patients receive cyclophosphamide 1.5 g/m2/day IV, carboplatin 200 mg/m2/day IV and thiotepa 125 mg/m2/day IV 24 hours on days -7 to -4. PBSC is reinjected on day -2 and 0 and G-CSF at 5ug/kg IV is administered as in arm I.", "Filgrastim: given IV or subcutaneously", "Carboplatin: under IV", "Cyclophosphamide: given IV", "\u00b7 thiotepa: under IV", "Transplantation of peripheral blood stem cells: patients receive autologous peripheral blood stem cells", "Total number of participants analysed: 51", "Type of measurement: Number", "Unit of measure: percentage of participants 55 (41-68)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/21 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}